Telix Pharmaceuticals Q2 2023 Quarterly Business Update

Telix Pharmaceuticals presents its Q2 2023 quarterly business update covering progress on its lead product Illuccix (TLX591-CDx) for prostate cancer imaging, which has received regulatory approvals from the TGA, FDA, and Health Canada. The presentation includes clinical development updates, financial performance, and strategic initiatives across the company's oncology imaging portfolio.